Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HOlmium Radioembolization as Adjuvant Treatment to Radiofrequency Ablation for Early STage Hepatocellular Carcinoma (HORA EST HCC)

NCT03437382 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT03437382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03437382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HOlmium Radioembolization as Adjuvant Treatment to Radiofrequency Ablation for Early STage Hepatocellular Carcinoma (HORA EST HCC)
Lead sponsor
Leiden University Medical Center
Phase
Not applicable
Overall status
Completed
Start date
July 1, 2018
Completion date
March 17, 2021
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early stage hcc, hcc